A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

Dec 12, 2012

FibroGen and Astellas Announce Initiation of Phase 3 Trial of FG-4592/ASP1517 for Treatment of Anemia of Chronic Kidney Disease

Read more about FibroGen and Astellas Announce Initiation of Phase 3 Trial of FG-4592/ASP1517 for Treatment of Anemia of Chronic Kidney Disease
Dec 12, 2012

Beyond Patent Cliff, Towards New Beyond Patent Cliff, Towards Towards New Growth Stage with Innovative Drugs

Read more about Beyond Patent Cliff, Towards New Beyond Patent Cliff, Towards Towards New Growth Stage with Innovative Drugs
Dec 11, 2012

Astellas and UMN announce Completion of Administration of Phase III Clinical Trials of Seasonal Flu Vaccine ASP7374

Read more about Astellas and UMN announce Completion of Administration of Phase III Clinical Trials of Seasonal Flu Vaccine ASP7374
Dec 11, 2012

Notice of Completion of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more about Notice of Completion of Acquisition of Own Shares
Dec 10, 2012

Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology

Highest level of single agent activity observed to date for FLT3-targeted therapy in relapsed/refractory AML

Read more about Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
Dec 4, 2012

AVEO and Astellas Announce Initiation of Patient Enrollment in Phase 2 Trial of Tivozanib in Combination with Paclitaxel in Patients with Advanced Triple Negative Breast Cancer

BATON-BC Trial Initiation Marks Entry into Third Tumor Type for Tivozanib Clinical Development Progra

CAMBRIDGE, Mass. and TOKYO, Japan, December 3, 2012 - AVEO Oncology (NASDAQ:AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced the initiation of patient enrollment in a randomized,...

Read more about AVEO and Astellas Announce Initiation of Patient Enrollment in Phase 2 Trial of Tivozanib in Combination with Paclitaxel in Patients with Advanced Triple Negative Breast Cancer
Dec 4, 2012

Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsule

Read more about Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsule
Nov 28, 2012

AVEO and Astellas Announce FDA Acceptance of NDA Filing for Tivozanib for the Treatment of Advanced Renal Cell Carcinoma

CAMBRIDGE, Mass. and TOKYO, Japan, November 28, 2012 -- AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that the U.S. Food and Drug Administration (FDA) has...

Read more about AVEO and Astellas Announce FDA Acceptance of NDA Filing for Tivozanib for the Treatment of Advanced Renal Cell Carcinoma
Nov 20, 2012

Astellas Submits Supplemental New Drug Application to FDA for Tarceva® as a First-Line Therapy in Genetically Distinct Form of Non-Small Cell Lung Cancer

Read more about Astellas Submits Supplemental New Drug Application to FDA for Tarceva® as a First-Line Therapy in Genetically Distinct Form of Non-Small Cell Lung Cancer
Nov 15, 2012

Astellas received the Notice from AstraZeneca Not to Exercise the Option to Acquire Diabetes Assets from Prosidion, a Subsidiary of Astellas

Tokyo, 15 November, 2012 –Astellas Pharma Inc. (Tokyo: 4503, ”Astellas”) announced today that it received a notice from AstraZeneca not to exercise an exclusive option to acquire the Phase...

Read more about Astellas received the Notice from AstraZeneca Not to Exercise the Option to Acquire Diabetes Assets from Prosidion, a Subsidiary of Astellas
Nov 6, 2012

Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting

Read more about Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
Nov 1, 2012

Astellas Announces Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more about Astellas Announces Acquisition of Own Shares
Oct 30, 2012

Astellas Pharma Announces Launch of Quattrovac® for Subcutaneous Injection Syringe, Adsorbed Purified Pertussis Diptheria Tetanus Inactivated Poliomyelitis (Sabin strain) Combined Vaccine

Read more about Astellas Pharma Announces Launch of Quattrovac® for Subcutaneous Injection Syringe, Adsorbed Purified Pertussis Diptheria Tetanus Inactivated Poliomyelitis (Sabin strain) Combined Vaccine
Oct 22, 2012

Astellas Enters Collaborative New Drug Discovery Research with AIST for Neglected Tropical Diseases Caused by Protozoan Parasites

- Through Drug Design Using Fragment Evolution -

Read more about Astellas Enters Collaborative New Drug Discovery Research with AIST for Neglected Tropical Diseases Caused by Protozoan Parasites
Oct 22, 2012

Astellas Launches Gonax® (Degarelix Acetate) for Subcutaneous Injection in Japan for Treating Prostate Cancer

Read more about Astellas Launches Gonax® (Degarelix Acetate) for Subcutaneous Injection in Japan for Treating Prostate Cancer
Oct 22, 2012

MYRBETRIQ™ (mirabegron), Overactive Bladder Treatment from Astellas, Now Available Through U.S. Pharmacies

Read more about MYRBETRIQ™ (mirabegron), Overactive Bladder Treatment from Astellas, Now Available Through U.S. Pharmacies
Oct 19, 2012

MIRABEGRON RECEIVES POSITIVE CHMP OPINION FOR TREATMENT OF OVERACTIVE BLADDER SYMPTOMS

Read more about MIRABEGRON RECEIVES POSITIVE CHMP OPINION FOR TREATMENT OF OVERACTIVE BLADDER SYMPTOMS
Oct 17, 2012

Astellas Pharma Inc.: Donation of Six Wheelchair Vans by Employee-Run Social Contribution Fund “Flying Star Fund”

Read more about Astellas Pharma Inc.: Donation of Six Wheelchair Vans by Employee-Run Social Contribution Fund “Flying Star Fund”
Oct 3, 2012

Astellas Announces Poster Presentation of SGLT2 Inhibitor (Ipragliflozin) Detailing Efficacy and Safety in Combination with Other Hypoglycemic Agents in Patients with Type 2 Diabetes at the European Association for the Study of Diabetes Meeting

Read more about Astellas Announces Poster Presentation of SGLT2 Inhibitor (Ipragliflozin) Detailing Efficacy and Safety in Combination with Other Hypoglycemic Agents in Patients with Type 2 Diabetes at the European Association for the Study of Diabetes Meeting
Oct 1, 2012

AVEO and Astellas Announce New Data Presented at ESMO 2012 Congress Demonstrating the Safety and Tolerability Profile of Tivozanib in Patients with Advanced Kidney Cancer First Patient Enrolled in TAURUS Patient Preference Study

CAMBRIDGE, Mass. and TOKYO, Japan, October 1, 2012 - AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced new data from the Phase 3 TIVO-1 trial (TIvozanib Versus...

Read more about AVEO and Astellas Announce New Data Presented at ESMO 2012 Congress Demonstrating the Safety and Tolerability Profile of Tivozanib in Patients with Advanced Kidney Cancer First Patient Enrolled in TAURUS Patient Preference Study
Sep 30, 2012

Medivation and Astellas Announce New Data From XTANDI® (enzalutamide) Pivotal Study

-- AFFIRM Study Data Presented Today at European Society of Medical Oncology (ESMO) --

Read more about Medivation and Astellas Announce New Data From XTANDI® (enzalutamide) Pivotal Study
Sep 28, 2012

AVEO and Astellas Announce Submission of New Drug Application for Tivozanib for the Treatment of Advanced Renal Cell Carcinoma

CAMBRIDGE, Mass. and TOKYO, Japan, September 28, 2012 -- AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that AVEO has submitted a New Drug Application (NDA) to...

Read more about AVEO and Astellas Announce Submission of New Drug Application for Tivozanib for the Treatment of Advanced Renal Cell Carcinoma
Sep 26, 2012

Astellas Included in Dow Jones Sustainability Asia Pacific Index for Second Consecutive Year

Tokyo, Japan, September 26, 2012 - Astellas Pharma Inc. (Tokyo:4503,“Astellas”) announced that it has been selected for the second consecutive year in the Dow Jones Sustainability Asia Pacific...

Read more about Astellas Included in Dow Jones Sustainability Asia Pacific Index for Second Consecutive Year
Sep 24, 2012

Astellas Submits U.S. New Drug Application for Tacrolimus Extended Release Capsules, a Prophylaxis of Organ Rejection in Transplant Recipients

Read more about Astellas Submits U.S. New Drug Application for Tacrolimus Extended Release Capsules, a Prophylaxis of Organ Rejection in Transplant Recipients
Sep 20, 2012

KEK and Astellas begin collaborative research to discover new drugs for neglected tropical diseases - Design of pharmaceuticals based on the three-dimensional structure of proteins using synchrotron X-ray crystallography -

Tokyo, Japan, September 20, 2012 –The High Energy Accelerator Research Organization (KEK) and Astellas Pharma Inc. (Tokyo:4503,“Astellas”) have today concluded an agreement to begin...

Read more about KEK and Astellas begin collaborative research to discover new drugs for neglected tropical diseases - Design of pharmaceuticals based on the three-dimensional structure of proteins using synchrotron X-ray crystallography -

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts